Signal Transduction and Targeted Therapy

Article	Citations
Cocktails of defined chemical compounds: sufficient to induce totipotency in embryonic stem cells	1763
Somatic mutant clone screening: scan for novel NASH target genes in mouse liver	1579
Dopamine as a teaching signal: understanding its role in shaping individual behavior	1404
Interaction between CDC6 and Tmod3 accelerates resistance to paclitaxel through focal adhesion assembly	1380
Recombinant XBB.1.5 boosters induce robust neutralization against KP.2- and KP.3-included JN.1 sublineages	1278
A donor PD-1+CD8+ TSCM-like regulatory subset mobilized by G-CSF alleviates recipient acute graft-versus-host-disease	1230
Correction: The Hippo signalling pathway and its implications in human health and diseases	1224
Cancer cell employs a microenvironmental neural signal trans-activating nucleus-mitochondria coordination to acquire stemness	1185
Boosting liver regeneration: kinase inhibitor as a new tool to prevent liver failure	1147
Pro-senescence neddylation inhibitor combined with a senescence activated β-galactosidase prodrug to selectively target cancer cells	1131
Comprehensive genomic and transcriptomic analyses reveal prognostic stratification for esophageal squamous cell carcinoma	1102
Robust neutralizing antibody response to the XBB.1.5 trivalent recombinant protein vaccine booster	1062
Next-generation mpox vaccines: efficacy of mRNA-1769 compared to modified vaccinia virus Ankara in non-human primates	1016
Correction: Ribosomal modification protein rimK-like family member A activates betaine-homocysteine S-methyltransferase 1 to ameliorate hepatic steatosis	1015
Moving towards precision psychiatry: the hard nut of depression	1013
Inducible CD147 up-regulation boosts extended SARS-CoV-2 infection triggering severe COVID-19 independent of ACE2	959
Chemo-photothermal synergy ignites antitumor immunity via ferroptosis	899
Animal models for COVID-19: advances, gaps and perspectives	884
Comparing acute versus AIDS ART initiation on HIV-1 integration sites and clonal expansion	872
CD4 T cell contact drives macrophage cell cycle G0-G1 transition	869
Gut microbes regulate the feeding center: a new discovery of Gut Brain Axis	854
Deciphering the molecular basis of lipoprotein recognition and transport by LolCDE	852
Retraction Note: BICC1 drives pancreatic cancer progression by inducing VEGF-independent angiogenesis	848
Peptide targeting the interaction of S protein cysteine-rich domain with Ezrin restricts pan-coronavirus infection	847
Dietary restriction interventions: lifespan benefits need resilience and are limited by immune compromise and genetics	828

Massively parallel interrogation of human functional variants modulating cancer immunosurveillance	823
SARS-CoV-2 envelope protein impairs airway epithelial barrier function and exacerbates airway inflammation via increased intracellular Cl− concentration	819
Identification of glutamine as a potential therapeutic target in dry eye disease	799
A broadly neutralizing antibody against the SARS-CoV-2 Omicron sub-variants BA.1, BA.2, BA.2.12.1, BA.4, and BA.5	787
Renal remodeling by CXCL10-CXCR3 axis-recruited mesenchymal stem cells and subsequent IL4I1 secretion in lupus nephritis	756
Cardiovascular ageing: hallmarks, signaling pathways, diseases and therapeutic targets	756
Viral vectored vaccines: design, development, preventive and therapeutic applications in human diseases	754
Photodynamic gel-bombs enhance tumor penetration and downstream synergistic therapies	749
A small molecule inhibitor of the UBE2F-CRL5 axis induces apoptosis and radiosensitization in lung cancer	731
Efficacy and safety of PD-1 blockade plus long-course chemoradiotherapy in locally advanced rectal cancer (NECTAR): a multi-center phase 2 study	720
Neutrophil extracellular traps in homeostasis and disease	719
Sensory neurons: unveiling the symphony of wound healing	714
Sintilimab (anti-PD-1 antibody) plus chidamide (histone deacetylase inhibitor) in relapsed or refractory extranodal natural killer T-cell lymphoma (SCENT): a phase Ib/II study	710
G protein-coupled receptors in neurodegenerative diseases and psychiatric disorders	703
Membraneless organelles in health and disease: exploring the molecular basis, physiological roles and pathological implications	696
Neoadjuvant nivolumab with or without platinum-doublet chemotherapy based on PD-L1 expression in resectable NSCLC (CTONG1804): a multicenter open-label phase II study	689
Metabolic reprogramming of proinflammatory macrophages by target delivered roburic acid effectively ameliorates rheumatoid arthritis symptoms	688
Immunotherapy in hematologic malignancies: achievements, challenges and future prospects	645
Phototherapy in cancer treatment: strategies and challenges	639
PD-1 and LAG-3: synergistic fostering of T cell exhaustion	639
“Good” fats, bad news: HDL-delivered vitamin E shields tumors from ferroptosis	637
Omicron spike protein: a clue for viral entry and immune evasion	602
From tuberculosis bedside to bench: UBE2B splicing as a potential biomarker and its regulatory mechanism	598
Concordance analysis of DNA and RNA profiling: The MD Anderson IMPACT2 study in precision oncology	598
Spatial TIME landscape and its prognostic value in the lung and brain tumor: location matters	580
Top(ological-operon) secret behind the long-range transcriptional coupling	572
D-lactate and glycerol as potential biomarkers of sorafenib activity in hepatocellular carcinoma	568
Aberrant epithelial cell interaction promotes esophageal squamous-cell carcinoma development and progression	557
Nanobody-based bispecific T-cell engager (Nb-BiTE): a new platform for enhanced T-cell immunotherapy	554
TSPAN32 suppresses chronic myeloid leukemia pathogenesis and progression by stabilizing PTEN	554
Potassium voltage-gated channel subfamily H member 2 (KCNH2) is a promising target for incretin secretagogue therapies	540
Beyond borders: the choroid plexus-immune communication during neuroinflammation	510
Development of a potent benzonitrile-based inhibitor of glutaminyl-peptide cyclotransferase-like protein (QPCTL) with antitumor efficacy	508
Microglia-derived nanovesicles synchronize macroautophagy and chaperone-mediated autophagy for Alzheimer’s disease therapy	502
SARS-CoV-2 infection of monocytes: balancing acts of antibodies and inflammasomes	499
Age-induced changes in lung microenvironment: from melanoma dormancy to outgrowth	493
Docking protein 6 (DOK6) selectively docks the neurotrophic signaling transduction to restrain peripheral neuropathy	481
Klotho in Osx+-mesenchymal progenitors exerts pro-osteogenic and anti-inflammatory effects during mandibular alveolar bone formation and repair	461
Unleashing the potential of bimetallic nanobomb-mediated STING pathway to enhance bispecific T-cell engager against colorectal cancer photo-immunotherapy	457
Preoperative pembrolizumab (anti-PD-1 antibody) combined with chemoradiotherapy for esophageal squamous cell carcinoma: a phase 1/2 trial (PALACE-2)	457
Bone-targeting engineered small extracellular vesicles carrying anti-miR-6359-CGGGAGC prevent valproic acid-induced bone loss	454
PIKfyve inhibitors against SARS-CoV-2 and its variants including Omicron	450
Non-small cell lung cancers (NSCLCs) oncolysis using coxsackievirus B5 and synergistic DNA-damage response inhibitors	441
Inhibition of RNA-binding proteins enhances immunotherapy in ovarian cancer	433
Drugging the intrinsically disordered transactivation domain of androgen receptor	433
Platelets and diseases: signal transduction and advances in targeted therapy	429
Harnessing innate immune pathways for therapeutic advancement in cancer	429
The RING finger protein family in health and disease	426
Lysophosphatidylethanolamine 18:1 drives clear cell renal cell carcinoma by stabilizing SIRT6 to reprogram lipid metabolism	421
Ninjurin-1 mediates cell lysis and detrimental inflammation of PANoptosis during influenza A virus infection	413

Signaling pathways involved in ischemic stroke: molecular mechanisms and therapeutic interventions	409
Mind-body control: a new perspective on motor neuron function	408
Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative diseases	408
Base editing: a promising tool to rescue spinal muscular atrophy	398
Targeting menin: a promising therapeutic strategy for susceptible acute leukemia subtypes	391
Discovery of IHMT-MST1-39 as a novel MST1 kinase inhibitor and AMPK activator for the treatment of diabetes mellitus	390
Ring finger protein 213 regulates B-cell receptor signaling, metabolism, and development in B lymphocytes	389
The consensus molecular subtypes of esophageal squamous cell carcinoma	387
Metaplastic epithelial cells: origination from stem cells and promotion of intestinal inflammation	384
Nascent mRNA damage: depot and disposal	382
Secreted LRPAP1 binds and triggers IFNAR1 degradation to facilitate virus evasion from cellular innate immunity	375
Correction: Durable and enhanced immunity against SARS-CoV-2 elicited by manganese nanoadjuvant formulated subunit vaccine	375
CNTNAP2 intracellular domain (CICD) generated by γ-secretase cleavage improves autism-related behaviors	375
Waning humoral immune responses to inactivated SARS-CoV-2 vaccines in patients with severe liver disease	374
Development of a leucine-rich repeat-containing protein 15-targeted radio-immunotheranostic approach to deplete pro-tumorigenic mechanisms and immunotherapy resistance	372
Landscape of antitumor CD4+ T cells in melanoma:unraveling novel HLA class II-driven immune escape	372
Intranasal booster using an Omicron vaccine confers broad mucosal and systemic immunity against SARS-CoV-2 variants	370
Spi-1 proto-oncogene regulates mRNA hypertranscription and malignant progression in head and neck cancer	366
Targeting fused in sarcoma (FUS): a novel antisense strategy for treating idiopathic pulmonary fibrosis	366
IRE1α: a gatekeeper of chemotherapy-induced immunogenicity in triple-negative breast cancer	358
Arterial inflammation after myocardial infarction: regulating the immune system	355
Urate-lowering therapy and kidney outcomes in patients with chronic kidney disease and hyperuricemia	354
Enhancer transcription profiling reveals an enhancer RNA-driven ferroptosis and new therapeutic opportunities in prostate cancer	351
A20 attenuates oxidized self-DNA-mediated inflammation in acute kidney injury	348
PD-1/LAG-3 signaling rewires T-cells via MYC inhibition	348
Targeting HECTD3-IKKα axis inhibits inflammation-related metastasis	347
Predicting the next move: tracking the complexity of lung cancer evolution and metastasis	342
Small molecules in the treatment of COVID-19	321
Rationale for multi-epitope TGFβ vaccination in pancreatic cancer: evidence from immunologic and clinical correlates	321
Linking B cell metabolism to immune regulation: the neurotransmitter GABA	320
SARS-CoV-2 Omicron subvariant BA.2.86: limited potential for global spread	314
Transferrin receptor 1 nuclear translocation facilitates tumor progression via p53-mediated chromatin interactions and genome-wide alterations	313
The cost of cure: cancer therapies sculpt somatic evolution and signaling landscapes in normal tissues	313
Semaphorin 3C (Sema3C) reshapes stromal microenvironment to promote hepatocellular carcinoma progression	311
Molecular insights of exercise therapy in disease prevention and treatment	311
STING aggravates ferroptosis-dependent myocardial ischemia-reperfusion injury by targeting GPX4 for autophagic degradation	311
RUNX1 promotes mitophagy and alleviates pulmonary inflammation during acute lung injury	309
Multicenter phase 1/2 study of onatasertib, a dual TORC1/2 inhibitor, combined with the PD-1 antibody toripalimab in advanced solid tumors	307
Mitochondrial heterogeneity in diseases	305
GRP75 triggers white adipose tissue browning to promote cancer-associated cachexia	301
High fructose consumption aggravates inflammation by promoting effector T cell generation via inducing metabolic reprogramming	292
Pathophysiological mechanisms and therapeutic approaches in obstructive sleep apnea syndrome	292
Autophagy, ferroptosis, pyroptosis, and necroptosis in tumor immunotherapy	289
Low levels of neutralizing antibodies against XBB Omicron subvariants after BA.5 infection	287
Pancreatic cancer: molecular pathogenesis and emerging therapeutic strategies	287
Epigenetic regulation in metabolic diseases: mechanisms and advances in clinical study	268
Signaling pathways involved in colorectal cancer: pathogenesis and targeted therapy	265
Lactate metabolism in human health and disease	263
DNA framework signal amplification platform-based high-throughput systemic immune monitoring	260
Remolding the tumor microenvironment by bacteria augments adoptive T cell therapy in advanced-stage solid tumors	257
Homeostasis and metabolism of iron and other metal ions in neurodegenerative diseases	255
Endoplasmic reticulum stress: molecular mechanism and therapeutic targets	252
Comprehensive snapshots of natural killer cells functions, signaling, molecular mechanisms and clinical utilization	250
Single-cell genomics: the human biomolecular and cell atlases	249
Induced regulatory T cells for therapy: targeting RBPJ to enhance stability and function	249
A new treatment for sarcoma extracted from combination of miRNA deregulation and gene association rules	247
Liquid biomarkers associate with TGF-β Type I receptor and hypoxia in kidney cancer	244
Post-fast refeeding: rise of intestinal stemness and mutagen-induced cancer risk through polyamine metabolism	241
2D4, a humanized monoclonal antibody targeting CD132, is a promising treatment for systemic lupus erythematosus	238
Ubiquitin-mediated stabilization of KDM5B drives chemoresistance via repression of dual-specificity phosphatase 4 in ovarian cancer	237
Mutually exclusive epigenetic modification on SIX6 with hypermethylation for precancerous stage and metastasis emergence tracing	232
Epigenetic regulation of TP53 is involved in prostate cancer radioresistance and DNA damage response signaling	231
RNA binding protein TIAR modulates HBV replication by tipping the balance of pgRNA translation	230
CRISPR gene editing of angiopoietin-like 3: toward one-time precision therapy for dyslipidaemia	228
C/EBPβ activation in vascular smooth muscle cells promotes hyperlipidemia-induced phenotypic transition and arterial stiffness	225
Personalized pharmacokinetic–pharmacodynamic guided therapy via an induced pluripotent stem cell–derived multi-organoid platform in NF1-mutant breast cancer	225
RNA interfering machinery: new insight into the Dicer-2 complexes in the dsRNA-processing cycle	224
Targeting complement hyperactivation: a novel therapeutic approach for severe pneumonia induced by influenza virus/staphylococcus aureus coinfection	222
Phosphorylation determines the glucose metabolism reprogramming and tumor-promoting activity of sine oculis homeobox 1	221
Early intermittent cholesterol exposure accelerates atherosclerosis: an oscillating amplifier calling for preemptive control	220
SYK-mediated epithelial cell state is associated with response to c-Met inhibitors in c-Met-overexpressing lung cancer	219
Gold nanoparticles combat enveloped RNA virus by affecting organelle dynamics	217
Gut microbiota modulation via repeated donor fecal transplantation improves motor and gastrointestinal symptoms in drug-naïve Parkinson’s disease: a randomized phase 2 trial	216
Pulsed electromagnetic fields inhibit atherosclerosis by regulating pyroptosis through membrane tension-mediated mechanosensitive channels	215
Targeting TM4SF1 exhibits therapeutic potential via inhibition of cancer stem cells	215
Back to pluripotency: fully chemically induced reboot of human somatic cells	212
Stem loop binding protein promotes SARS-CoV-2 replication via -1 programmed ribosomal frameshifting	208
The deacetylases HDAC1/HDAC2 control JAK2V617F-STAT signaling through the ubiquitin ligase SIAH2	207
B-cell immune checkpoint TIM-1: a potential target for tumour immunotherapy	206
SARS-CoV-2 N protein enhances the anti-apoptotic activity of MCL-1 to promote viral replication	204

Current landscape of innovative drug development and regulatory support in China	203
Programmable synthetic receptors: the next-generation of cell and gene therapies	202
Multi-omics analysis reveals RNA splicing alterations and their biological and clinical implications in lung adenocarcinoma	199
Targeting BCL9/BCL9L enhances antigen presentation by promoting conventional type 1 dendritic cell (cDC1) activation and tumor infiltration	199
A phase II clinical trial of toripalimab in advanced solid tumors with polymerase epsilon/polymerase delta (POLE/POLD1) mutation	197
Preventing trogocytosis by cathepsin B inhibition augments CAR T-cell function	197
SRY-Box transcription factor 9 triggers YAP nuclear entry via direct interaction in tumors	196
Signaling pathways and targeted therapies for psoriasis	195
Glioblastoma at the crossroads: current understanding and future therapeutic horizons	194
Deconstructing the intra-tumor subclonal heterogeneity of lung synchronous ground-glass nodules using whole-genome sequencing	191
mRNA-based therapeutics: powerful and versatile tools to combat diseases	191
Angiogenic signaling pathways and anti-angiogenic therapy for cancer	191
Oocyte TET3: an epigenetic modifier responsible for maternal inheritance of glucose intolerance	190
Targeting tumor microenvironment with antibody-guided IL-2 pro-cytokine promotes and rejuvenates dysfunctional CD8+ T cells	189
Surufatinib plus toripalimab combined with etoposide and cisplatin as first-line treatment in advanced small-cell lung cancer patients: a phase Ib/II trial	189
I prostanoid receptor activation attenuates pressure overload-induced cardiac hypertrophy by enhancing glucose oxidation	189
Modularization of adhesion G protein-coupled receptor (aGPCR) structure: how alternative splicing regulates synaptogenesis	188
Adhesion G protein-coupled receptor latrophilin 1 (ADGRL1): a novel regulator of glucose and energy homeostasis	183
Aptamers targeting SARS-CoV-2 nucleocapsid protein exhibit potential anti pan-coronavirus activity	182
Synthetic lethality by PARP inhibitors: new mechanism uncovered based on unresolved transcription-replication conflicts	181
Oit3, a promising hallmark gene for targeting liver sinusoidal endothelial cells	180
BMX inhibition overcomes small cell lung cancer chemoresistance by stabilizing E2F1 via ERK1/2-Cyclin D1/CDK4/6 axis	179
Sintilimab (anti-PD-1 antibody) combined with high-dose methotrexate, temozolomide, and rituximab (anti-CD20 antibody) in primary central nervous system lymphoma: a phase 2 study	178
Farnesyltransferase inhibitor lonafarnib suppresses respiratory syncytial virus infection by blocking conformational change of fusion glycoprotein	178
Activated STING: an ion channel to trigger non-interferon-related functions	178
Baseline gut microbiota and metabolome predict durable immunogenicity to SARS-CoV-2 vaccines	174
Tissue-adapted Tregs harness inflammatory signals to promote intestinal repair from therapy-related injury	172
Environment impacts sexual preference: dopamine sends signals under pressure to decide which sex you like	172
Balancing memory in sleep: firing barrages as a circuit breaker for reactivation	171
Arterial stiffness and vascular aging: mechanisms, prevention, and therapy	170
Bat organoid platform: revolutionizing zoonotic virus research and pandemic preparedness	170
Checkpoint blockade therapy in Hodgkin lymphoma: improved response through combination with JAK inhibition	166
Reframing cancer cachexia: the vagal brain–liver axis as a novel neuro-metabolic target	166
Universal scaling law: transcription factors homeostatically control promoter activity	165
Potent and selective LSD1 inhibitor DC551040 reveals a promising combination therapy for AML with insight into epigenetic dysregulation	164
Time’s up: mutation rate and lifespan	163
Asialoglycoprotein receptor 1 promotes SARS-CoV-2 infection of human normal hepatocytes	162
A PD-L1-targeting chimeric switch receptor enhances efficacy of CAR-T cell for pleural and peritoneal metastasis	161
Intratumoral microbiota: roles in cancer initiation, development and therapeutic efficacy	161
Targeting PI3K inhibitor resistance in breast cancer with metabolic drugs	160
ALYREF mediates RNA m5C modification to promote hepatocellular carcinoma progression	159
Targeting signaling pathways in prostate cancer: mechanisms and clinical trials	156
The role of ER-associated degradation and ER-phagy in health and disease	155
Neoleukin-2/15-armored CAR-NK cells sustain superior therapeutic efficacy in solid tumors via c-Myc/NRF1 activation	155
Signaling pathways in obesity: mechanisms and therapeutic interventions	155
To metabolomics and beyond: a technological portfolio to investigate cancer metabolism	153
Amyloid β-based therapy for Alzheimer’s disease: challenges, successes and future	153
Role of the miR-301a/Fra-2/GLIPR1 axis in lung cancer cisplatin resistance	152
Toripalimab combined with lenvatinib and GEMOX is a promising regimen as first-line treatment for advanced intrahepatic cholangiocarcinoma: a single-center, single-arm, phase 2 study	151
Neuro-immune crosstalk in cancer: mechanisms and therapeutic implications	150
Redox regulation: mechanisms, biology and therapeutic targets in diseases	150
Toripalimab plus chemotherapy for first line treatment of advanced non-small cell lung cancer (CHOICE-01): final OS and biomarker exploration of a randomized, double-blind, phase 3 trial	150
Intranasal adenovirus-vectored Omicron vaccine induced nasal immunoglobulin A has superior neutralizing potency than serum antibodies	148
Hypoxia-inducible factor upregulation by roxadustat attenuates drug reward by altering brain iron homoeostasis	147
Artificial intelligence in cancer target identification and drug discovery	144
Targeted protein degradation: advances in drug discovery and clinical practice	144
Finotonlimab (PD-1 inhibitor) plus bevacizumab (bevacizumab biosimilar) as first-tier therapy for late-stage hepatocellular carcinoma: a randomized phase 2/3 trial	143
Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential	143
Route, origin & valence matter: towards sophisticated next-generation vaccines to cope with the COVID-19 pandemic	142
Curse and blessing: upregulation of oncogenes upon treatment with hypomethylating agents in myelodysplastic syndrome	141
DDX39B K63-linked ubiquitination mediated by TRIM28 promotes NSCLC metastasis by enhancing ECAD lysosomal degradation	140
PARP1-DNA co-condensation: the driver of broken DNA repair	140
CXCR4-modification enhances CAR-T efficacy by improving tumor tracking and bone marrow homing in B-cell malignancies	139
Clinical and biomarker analyses of SHR-1701 combined with famitinib in patients with previously treated advanced biliary tract cancer or pancreatic ductal adenocarcinoma: a phase II trial	138
Correction: CDK4/6 inhibition blocks cancer metastasis through a USP51-ZEB1-dependent deubiquitination mechanism	137
DRC3 is an assembly adapter of the nexin-dynein regulatory complex functional components during spermatogenesis in humans and mice	137
A systemic look at pancreatic cancer patients: Predicting metastasis by studying the liver	137
FGF7 enhances the expression of ACE2 in human islet organoids aggravating SARS-CoV-2 infection	137
Astrocytic gamma-aminobutyric acid dysregulation as a therapeutic target for posttraumatic stress disorder	136
Cross-neutralization and cross-protection among SARS-CoV-2 viruses bearing different variant spikes	136
SLC7A11: a new regulator in diabetic wound healing	134
Hypocretin neuron hyperexcitability in the hypothalamus: a newly discovered culprit in aging-related sleep impairment	133
Elemene sensitizes pancreatic cancer cells to bortezomib by enhancing proteasome inhibition via molecular patch mechanism	133
Combination therapy with saxagliptin and vitamin D for the preservation of β-cell function in adult-onset type 1 diabetes: a multi-center, randomized, controlled trial	132
Artificial intelligence propels lung cancer screening: innovations and the challenges of explainability and reproducibility	131
Genetic differences between primary and metastatic cancer: a pan-cancer whole-genome comparison study	131
Uveal melanoma with a GNA11/GNAQ mutation secretes VEGF for systemic spread	131
First-line treatment with chemotherapy, surufatinib (an angio-immuno kinase inhibitor), and camrelizumab (an anti-PD-1 antibody) for locally advanced or metastatic pancreatic ductal adenocarcinoma: a	131
XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal c	130
CHIKV mRNA vaccines encoding conserved structural/envelope proteins confer broad cross-lineage protection against infection	129
Patient-reported outcomes of rezvilutamide versus bicalutamide in combination with androgen deprivation therapy in high-volume metastatic hormone-sensitive prostate cancer patients (CHART): a randomiz	128
Bioengineered iPSC-derived human macrophages with increased angiotensin-converting enzyme (ACE) expression suppress solid tumor growth	128
Integrative phosphoproteomics defines two biologically distinct groups of KMT2A rearranged acute myeloid leukaemia with different drug response phenotypes	127
Human cross-tissue cell atlases: unprecedented resources towards systematic understanding of physiology and diseases	126
Discovery of IHMT-337 as a potent irreversible EZH2 inhibitor targeting CDK4 transcription for malignancies	126
GPR162 activates STING dependent DNA damage pathway as a novel tumor suppressor and radiation sensitizer	124
IL-17 signaling in skin repair: safeguarding metabolic adaptation of wound epithelial cells	122
Oncolytic viruses: advanced strategies in cancer therapy	122
Human adipose and umbilical cord mesenchymal stem cell-derived extracellular vesicles mitigate photoaging via TIMP1/Notch1	121
The heterogeneous immune landscape between lung adenocarcinoma and squamous carcinoma revealed by single-cell RNA sequencing	119
Mutation-independent gene knock-in therapy targeting 5′UTR for autosomal dominant retinitis pigmentosa	119
Induced pluripotent stem cells (iPSCs): molecular mechanisms of induction and applications	119
The gasdermin family: emerging therapeutic targets in diseases	118
Neoadjuvant oncolytic virus orienx010 and toripalimab in resectable acral melanoma: a phase Ib trial	117
METTL14 downregulation drives S100A4+ monocyte-derived macrophages via MyD88/NF-κB pathway to promote MAFLD progression	117